CDKN2A and Miyoshi myopathy: Inactivation of BAP1 cooperates with the loss of either CDKN2A/2B (cyclin-dependent kinase inhibitor 2A/2B) or NF2 (neuriofibromin 2) to drive the development of MM, highlighting its role in cell transformation (48).